Literature DB >> 23454864

Immune activation and HIV persistence: considerations for novel therapeutic interventions.

Hiroyu Hatano1.   

Abstract

PURPOSE OF REVIEW: One of the potential barriers to current HIV cure strategies is the persistence of elevated levels of immune activation despite otherwise effective antiretroviral therapy (ART). The purpose of this review is to examine the relationship between immune activation and HIV persistence, and to review the novel therapeutic interventions that are currently being pursued to target immune activation in treated HIV disease. RECENT
FINDINGS: Multiple groups have consistently observed that elevated levels of inflammation, immune activation, and immune dysfunction persist in ART-treated individuals, despite the successful suppression of plasma viremia. Increased immune activation may lead to viral persistence through multiple mechanisms. Several novel interventions aimed at decreasing persistent immune activation are being pursued and include studies aimed at decreasing low-level viral replication, approaches aimed at decreasing microbial translocation, interventions to treat co-infections, and therapies that directly target immune activation.
SUMMARY: There appears to be a clear and consistent relationship between immune activation and viral persistence in treated HIV disease. Whether this relationship is causal or mediated through other mechanisms is still unknown. Small-scale, pathogenesis-oriented interventional studies are necessary to further evaluate this relationship and the effect of potential interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454864      PMCID: PMC4041488          DOI: 10.1097/COH.0b013e32835f9788

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  60 in total

1.  Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy.

Authors:  Timothy W Schacker; Phuong L Nguyen; Esteban Martinez; Cavan Reilly; Jose M Gatell; Andrzej Horban; Elzbieta Bakowska; Baiba Berzins; Remko van Leeuwen; Steven Wolinsky; Ashley T Haase; Robert L Murphy
Journal:  J Infect Dis       Date:  2002-09-20       Impact factor: 5.226

2.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

3.  Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients.

Authors:  K Sharma; B O Eltayeb; T A McGowan; S R Dunn; B Alzahabi; R Rohde; F N Ziyadeh; E J Lewis
Journal:  Am J Kidney Dis       Date:  1999-11       Impact factor: 8.860

Review 4.  Mechanisms of HIV-associated lymphocyte apoptosis.

Authors:  A D Badley; A A Pilon; A Landay; D H Lynch
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

7.  Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis.

Authors:  Timothy W Schacker; Phuong L Nguyen; Gregory J Beilman; Steven Wolinsky; Matthew Larson; Cavan Reilly; Ashley T Haase
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

8.  Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells.

Authors:  Martyn A French; Martin S King; Jean M Tschampa; Barbara A da Silva; Alan L Landay
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

9.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

View more
  41 in total

1.  Predict disease progression from T-cell phenotypes in northern pig-tailed macaques (Macaca leonina) during SIVmac239 infection.

Authors:  Ming-Xu Zhang; Hong-Yi Zheng; Jin Jiang; Jia-Hao Song; Min Chen; Yu Xiao; Xiao-Dong Lian; Tian-Zhang Song; Ren-Rong Tian; Wei Pang; Yong-Tang Zheng
Journal:  Immunology       Date:  2017-08-14       Impact factor: 7.397

2.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 3.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

Review 4.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

5.  The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.

Authors:  Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream
Journal:  AIDS       Date:  2015-02-20       Impact factor: 4.177

6.  Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.

Authors:  Iart Luca Shytaj; Gabrielle Nickel; Eric Arts; Nicholas Farrell; Mauro Biffoni; Ranajit Pal; Hye Kyung Chung; Celia LaBranche; David Montefiori; Diego Vargas-Inchaustegui; Marjorie Robert-Guroff; Mark G Lewis; Jonah B Sacha; Anna Teresa Palamara; Andrea Savarino
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 7.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

Review 8.  Understanding HIV latency: the road to an HIV cure.

Authors:  Matthew S Dahabieh; Emilie Battivelli; Eric Verdin
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 9.  Cytomegalovirus and HIV: A Dangerous Pas de Deux.

Authors:  Sara Gianella; Scott Letendre
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

Review 10.  Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.

Authors:  Peter W Hunt; Sulggi A Lee; Mark J Siedner
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.